Kiniksa Pharmaceuticals International, plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Kiniksa Pharmaceuticals International, plc (KNSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.13 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-02-28
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.13M shares, a 27.16% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.93M shares, a 12.82% increase from fiscal 2021.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 2.60M shares, a 31.58% decline from fiscal 2020.
- Kiniksa Pharmaceuticals International, plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 3.79M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|
| 2023-12-31 | 2.13M shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 2.93M shares 10-K · filed 2023-03-02 |
| 2021-12-31 | 2.60M shares 10-K · filed 2022-02-24 |
| 2020-12-31 | 3.79M shares 10-K · filed 2021-02-25 |